Allergy

For patients with chronic rhinosinusitis, seasonal allergies may only make the condition feel worse for patients, though the relationship is still poorly defined.

The findings in a recent phase 3 clinical study may allow Kalvista Pharma to seek FDA approval for this potential hereditary angioedema treatment option.

In this interview, Palmer shares several of the key findings and their implications for the future of this patient population.

This research points to the notion that omalizumab may help individuals in more ways than a reduction of their sinonasal symptoms.

This research into EDS-FLU is significant, as there remain no medications approved by the FDA for chronic rhinosinusitis without nasal polyps.

This research had been conducted to look into prior studies linking daily pollen counts to respiratory allergic health outcomes.

This study looked at results of DOC, allergy risk level risk distinctions, and rationale for families and physicians to move forward with DOC.

The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.

From breakthroughs in disease intervention and vaccines, to global developments in air quality and COVID-19, Lungcast reflects on the people and stories that shaped this year in pulmonology.

This review of telehealth use among adolescents with allergic conditions synthesized evidence on patients’ transition to self-management of their conditions.

This research highlights the close relationship between pollen-induced allergic rhinitis, sensitization, and asthma.

This represented the first in human research focused on assessing the best dosing regimen of mannan-conjugated birch pollen allergoids for those with birch pollen–induced allergic rhinoconjunctivitis.

This new recommendation by the European Academy of Allergy and Clinical Immunology was put forward to help guide clinical practices.

Data show how care providers shifted their mindsets to prioritize efficacy, safety, tolerability and availability factors during the 2022 formula supply shortage and recall crises.

This new research could allow for limitations related to safety that could promote mitigation of ambient air pollution and protect those with allergies.

An institution's review of prescriptions in the first year since dupilumab's historic FDA approval for eosinopihlic esophagitis shows patients waited a mean 46 days to initiate the biologic therapy.

This new analysis was described as the first estimate on the prevalence in Europe of specific TNA and sensitization.

Amid the escalating threat of wildfires due to climate change, the medical and public health communities face an increasing responsibility to develop robust emergency response plans to safeguard patients and healthcare infrastructure.

The investigators of this new data note that integration using a standardized process which is EMR-based may be the next thing to move for, to better address the overreporting of penicillin allergy.

This new research into detergent’s impact on human skin barrier dysfunction may lead to investigation by public health authorities in the near future due to its implications.

In this interview, Dr. Kim described his response to the FDA’s decision not to approve the intranasal epinephrine spray treatment for anaphylaxis and other severe allergic reactions.

Results from EoE KIDS showed 68% of patients on a higher dose of dupilumab and 58% of patients on a lower dose achieved significant histological disease remission.

The FDA's announcement requesting further study represents a step back in the process of 'neffy' becoming the first needle-free nasal spray epinephrine alternative.

This segment of Dr. Kim’s interview featured a discussion on the potential advantages and disadvantages of the new ARS-1 epinephrine nasal spray being considered by the FDA.

In a new interview with the HCPLive editorial team, Edwin H. Kim, MD, spoke about the new ARS-1 (Neffy) intranasal epinephrine spray for patients having Type 1 allergic reactions as well as the FDA's upcoming decision on the treatment.